Indian stocks: Visit www.stage2stocks.com →

FibroBiologics, Inc.

Stage 1 · Basing · week 9

As of Oct 22, 2026, FibroBiologics is in Stage 1, the basing phase, now in week 9 (since Aug 26, 2026). It closed at $1.02, 88.3% below its 52-week high and below its 200-day average, which is falling.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. More about the company

$1.02
+2.72% today
$7.2M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is FBLG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2024-01-31 → 2026-10-22
S? 41w
S4 64w
S4 21w
2024-01-312026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S1 3w → S4 64w → S1 4w → S4 21w → S1 8w current
Total tracked: 142 weeks across 6 stage runs.

FBLG among Biotechnology506th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…506FBLGStage 1 · wk 98−23.3%
vs 52W High
-88.3%
$0.63 lo$8.74 hi
88.3% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 9
1w13w26w
Week 9, base building
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-60.1%
200 DMA: $2.56 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.77x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-23.3%
3M
+43.3%
6M
-32.5%
YTD
-78.8%
1Y
-87.8%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S1
Wk 9 · Vol 1.77x
2026-10-21S1
Wk 8 · Vol 0.57x
2026-10-20S1
Wk 8 · Vol 0.41x
2026-10-19S1
Wk 8 · Vol 0.76x
2026-10-16S1
Wk 8 · Vol 0.15x
2026-10-15S1
Wk 8 · Vol 0.66x
2026-10-14S1
Wk 7 · Vol 0.46x
2026-10-13S1
Wk 7 · Vol 0.33x
2026-10-12S1
Wk 7 · Vol 0.63x
2026-10-09S1
Wk 7 · Vol 0.76x
2026-10-08S1
Wk 7 · Vol 0.30x
2026-10-07S1
Wk 6 · Vol 0.99x
Moving averages & range
50 DMA
$1.33
200 DMA
$2.56
52W High
$8.74
52W Low
$0.63
5D Low
$0.92
Resistance levels (recent highs)
20d High
$1.39
60d High
$2.11
120d High
$2.11
250d High
$8.74
Next resistance
+36.3%
to 20d High
ROE
-660.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.3

FibroBiologics: quick answers

What stage is FibroBiologics in?

As of Oct 22, 2026, FibroBiologics (FBLG) is in Stage 1, the basing phase. It entered Stage 1 on Aug 26, 2026 and is in week 9. What the four stages mean

Is FibroBiologics in an uptrend?

Not yet. FibroBiologics is in Stage 1, a base that can come before an uptrend. It trades 60.1% below its 200-day average, which is falling.

How far is FibroBiologics from its 52-week high?

FibroBiologics closed at $1.02 on Oct 22, 2026, 88.3% below its 52-week high of $8.74. Its 52-week low is $0.63.

How has FibroBiologics performed over the past year?

As of Oct 22, 2026, FibroBiologics is down 87.8% over the past year and down 78.8% so far in 2026.

Which sector and industry is FibroBiologics in?

FibroBiologics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.